Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Fogel

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Drug Discovery Today|October 29, 2017
Indacaterol/glycopyrronium: a dual bronchodilator for COPDDonald Banerji, Robert Fogel, Francesco Patalano
The New Phytologist|April 20, 2021
The demography of fine roots in response to patches of water and nitrogenKurt S Pregitzer, Ronald L Hendrick, Robert Fogel
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily ActivitiesDonald A Mahler, Dorothy L Keininger, Karen Mezzi, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 2, 2014
Addressing unmet needs in the treatment of COPDFrancesco Patalano, Donald Banerji, Peter D'Andrea, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 23, 2019
Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD populationJørgen Vestbo, Claus F Vogelmeier, Mark Small, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE StudiesKenneth R Chapman, Eric D Bateman, Hungta Chen, et al.
COPD|June 9, 2017
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE ProgramIoanna Tsiligianni, Karen Mezzi, Sebastian Fucile, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 19, 2020
Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized StudyKimihiro Okubo, Mitsuhiro Okano, Norio Sato, et al.
Respiratory Investigation|November 26, 2016
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISEKazuhisa Asai, Kazuto Hirata, Shu Hashimoto, et al.
COPD|April 17, 2018
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL StudyKonstantinos Kostikas, Maryam Aalamian-Mattheis, Veronica Anna Pagano, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Drug Discovery Today|October 29, 2017
Indacaterol/glycopyrronium: a dual bronchodilator for COPDDonald Banerji, Robert Fogel, Francesco Patalano
The New Phytologist|April 20, 2021
The demography of fine roots in response to patches of water and nitrogenKurt S Pregitzer, Ronald L Hendrick, Robert Fogel
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily ActivitiesDonald A Mahler, Dorothy L Keininger, Karen Mezzi, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 2, 2014
Addressing unmet needs in the treatment of COPDFrancesco Patalano, Donald Banerji, Peter D'Andrea, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 23, 2019
Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD populationJørgen Vestbo, Claus F Vogelmeier, Mark Small, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE StudiesKenneth R Chapman, Eric D Bateman, Hungta Chen, et al.
COPD|June 9, 2017
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE ProgramIoanna Tsiligianni, Karen Mezzi, Sebastian Fucile, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 19, 2020
Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized StudyKimihiro Okubo, Mitsuhiro Okano, Norio Sato, et al.
Respiratory Investigation|November 26, 2016
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISEKazuhisa Asai, Kazuto Hirata, Shu Hashimoto, et al.
COPD|April 17, 2018
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL StudyKonstantinos Kostikas, Maryam Aalamian-Mattheis, Veronica Anna Pagano, et al.
Pageof 4